Free Trial

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earns "Overweight" Rating from Cantor Fitzgerald

Arrowhead Pharmaceuticals logo with Medical background

Cantor Fitzgerald reissued their overweight rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR - Free Report) in a report released on Thursday morning, Benzinga reports.

A number of other research analysts also recently commented on ARWR. Morgan Stanley lowered their price target on shares of Arrowhead Pharmaceuticals from $36.00 to $27.00 and set an equal weight rating for the company in a report on Monday, May 13th. The Goldman Sachs Group initiated coverage on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, June 5th. They set a neutral rating and a $31.00 target price on the stock. HC Wainwright reaffirmed a buy rating and set a $90.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, June 11th. Finally, Chardan Capital reaffirmed a buy rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, June 3rd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average target price of $47.89.

Check Out Our Latest Stock Report on Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR traded up $0.21 during midday trading on Thursday, hitting $23.79. 881,566 shares of the company traded hands, compared to its average volume of 1,323,473. The firm has a 50 day moving average of $24.07 and a 200-day moving average of $28.25. Arrowhead Pharmaceuticals has a 52 week low of $20.67 and a 52 week high of $39.83. The stock has a market cap of $2.95 billion, a price-to-earnings ratio of -5.60 and a beta of 0.94.


Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.96). Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative return on equity of 140.72%. During the same quarter in the prior year, the company posted $0.45 EPS. The business's quarterly revenue was down 100.0% compared to the same quarter last year. Sell-side analysts predict that Arrowhead Pharmaceuticals will post -3.05 earnings per share for the current fiscal year.

Insider Activity at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Victoria Vakiener sold 1,799 shares of the firm's stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $23.31, for a total value of $41,934.69. Following the completion of the sale, the director now directly owns 30,205 shares in the company, valued at $704,078.55. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 4.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several institutional investors have recently bought and sold shares of ARWR. Washington Trust Advisors Inc. acquired a new position in Arrowhead Pharmaceuticals during the fourth quarter valued at $25,000. Neo Ivy Capital Management acquired a new position in Arrowhead Pharmaceuticals during the fourth quarter valued at $41,000. Quest Partners LLC acquired a new position in Arrowhead Pharmaceuticals during the fourth quarter valued at $45,000. Friedenthal Financial acquired a new position in Arrowhead Pharmaceuticals during the fourth quarter valued at $51,000. Finally, Headlands Technologies LLC lifted its position in Arrowhead Pharmaceuticals by 7,696.8% during the first quarter. Headlands Technologies LLC now owns 2,417 shares of the biotechnology company's stock valued at $69,000 after purchasing an additional 2,386 shares during the period. 62.61% of the stock is currently owned by institutional investors and hedge funds.

About Arrowhead Pharmaceuticals

(Get Free Report)

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

Further Reading

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Should you invest $1,000 in Arrowhead Pharmaceuticals right now?

Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.

While Arrowhead Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

CPI News Breakdown: Key Market Moves to Follow
Understanding Oversold Stocks
Inside Pelosi’s Latest Stock Moves

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines